Cargando…
Analysis of integrated clinical trial protocols in early phases of medicinal product development
PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and m...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684304/ https://www.ncbi.nlm.nih.gov/pubmed/28921395 http://dx.doi.org/10.1007/s00228-017-2335-y |
_version_ | 1783278448538550272 |
---|---|
author | Fruhner, Kevin Hartmann, Gunther Sudhop, Thomas |
author_facet | Fruhner, Kevin Hartmann, Gunther Sudhop, Thomas |
author_sort | Fruhner, Kevin |
collection | PubMed |
description | PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and more popular. The aims of the present study were to investigate the usage and the impact of integrated protocols on regulatory activities and to find the motivation for their increasing use. METHODS: Two thousand nine hundred sixty-nine phase I and I/II CTAs submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) during the time period from August 1, 2004, until August 31, 2014, were analysed with regard to protocol and sponsor status, duration until initial authorisation and the number of substantial amendments and their respective approval times. Additionally, applicants who submitted integrated protocols to BfArM were interviewed with respect to their opinion on integrated protocols in an online survey. RESULTS: The percentage of integrated protocols has constantly increased by approximately 10% within the last 10 years from 17.9% in 2004 to 28.2% in 2014. It could be shown that authorisation procedures with single integrated protocols take significantly longer until initial authorisation (58 vs. 53 days) requires more substantial amendments (1.9 vs. 1.2 amendments per CTA) and the approval of the entirety of amendments takes longer to process as compared to standard protocols (22 vs. 14 days). Nevertheless, applicants prefer the use of integrated protocols due to higher time and cost economy for the entire phase I development process. CONCLUSION: Although clinical trials (CTs) following integrated protocols are partly more time-consuming and costly, still, time and/or money may be saved during drug development due to the fact that overall, fewer CTs are needed than with standard protocols. Hence, the main reason for the increasing use of integrated protocols is improved time and cost efficiencies when conducting CTs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-017-2335-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5684304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-56843042017-11-27 Analysis of integrated clinical trial protocols in early phases of medicinal product development Fruhner, Kevin Hartmann, Gunther Sudhop, Thomas Eur J Clin Pharmacol Clinical Trial PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and more popular. The aims of the present study were to investigate the usage and the impact of integrated protocols on regulatory activities and to find the motivation for their increasing use. METHODS: Two thousand nine hundred sixty-nine phase I and I/II CTAs submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) during the time period from August 1, 2004, until August 31, 2014, were analysed with regard to protocol and sponsor status, duration until initial authorisation and the number of substantial amendments and their respective approval times. Additionally, applicants who submitted integrated protocols to BfArM were interviewed with respect to their opinion on integrated protocols in an online survey. RESULTS: The percentage of integrated protocols has constantly increased by approximately 10% within the last 10 years from 17.9% in 2004 to 28.2% in 2014. It could be shown that authorisation procedures with single integrated protocols take significantly longer until initial authorisation (58 vs. 53 days) requires more substantial amendments (1.9 vs. 1.2 amendments per CTA) and the approval of the entirety of amendments takes longer to process as compared to standard protocols (22 vs. 14 days). Nevertheless, applicants prefer the use of integrated protocols due to higher time and cost economy for the entire phase I development process. CONCLUSION: Although clinical trials (CTs) following integrated protocols are partly more time-consuming and costly, still, time and/or money may be saved during drug development due to the fact that overall, fewer CTs are needed than with standard protocols. Hence, the main reason for the increasing use of integrated protocols is improved time and cost efficiencies when conducting CTs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-017-2335-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-09-18 2017 /pmc/articles/PMC5684304/ /pubmed/28921395 http://dx.doi.org/10.1007/s00228-017-2335-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Trial Fruhner, Kevin Hartmann, Gunther Sudhop, Thomas Analysis of integrated clinical trial protocols in early phases of medicinal product development |
title | Analysis of integrated clinical trial protocols in early phases of medicinal product development |
title_full | Analysis of integrated clinical trial protocols in early phases of medicinal product development |
title_fullStr | Analysis of integrated clinical trial protocols in early phases of medicinal product development |
title_full_unstemmed | Analysis of integrated clinical trial protocols in early phases of medicinal product development |
title_short | Analysis of integrated clinical trial protocols in early phases of medicinal product development |
title_sort | analysis of integrated clinical trial protocols in early phases of medicinal product development |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684304/ https://www.ncbi.nlm.nih.gov/pubmed/28921395 http://dx.doi.org/10.1007/s00228-017-2335-y |
work_keys_str_mv | AT fruhnerkevin analysisofintegratedclinicaltrialprotocolsinearlyphasesofmedicinalproductdevelopment AT hartmanngunther analysisofintegratedclinicaltrialprotocolsinearlyphasesofmedicinalproductdevelopment AT sudhopthomas analysisofintegratedclinicaltrialprotocolsinearlyphasesofmedicinalproductdevelopment |